Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...
Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback